CTOs on the Move

Bio-Path Holdings

www.biopathholdings.com

 
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bio-Path Holdings raised $13M on 02/16/2021

Similar Companies

Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.

Zwanger Pesiri Radiology

Zwanger Pesiri Radiology is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regional Clinical Research

Regional Clinical Research is a Endicott, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eos Biotechnology

Eos Biotechnology , Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anichem

Anichem is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.